Q-omics provides the consensus-scored UBA5 profile across patient tissues and cancer cell-line models. UBA5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UBA5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, UBA5 RNA expression shows 20,647 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where UBA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBA5 survival associations across molecular data types. UBA5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBA5 RNA expression–survival associations across cancer types. High UBA5 expression shows unfavorable associations in ACC, LUSC, PAAD and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UBA5 RNA expression.
This table summarizes UBA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UBA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBA5 shows lower tumor expression in THCA and KIRP and higher tumor expression in KIRC, HNSC, LIHC and BRCA. The KIRC box plot shows higher UBA5 RNA expression in tumor versus normal tissue (log2 FC = +0.931, t-test p < 0.001).
This table shows molecular features associated with UBA5 in patient tissues and cancer cell lines. In patient samples, UBA5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UBA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
